These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 11535994)
21. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628 [TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Yanada M; Yamamoto K; Emi N; Naoe T; Suzuki R; Taji H; Iida H; Shimokawa T; Kohno A; Mizuta S; Maruyama F; Wakita A; Kitaori K; Yano K; Hamaguchi M; Hamajima N; Morishima Y; Kodera Y; Sao H; Morishita Y Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425 [TBL] [Abstract][Full Text] [Related]
23. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242 [TBL] [Abstract][Full Text] [Related]
24. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674 [TBL] [Abstract][Full Text] [Related]
25. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988 [TBL] [Abstract][Full Text] [Related]
26. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322 [TBL] [Abstract][Full Text] [Related]
27. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Winston DJ; Busuttil RW Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129 [TBL] [Abstract][Full Text] [Related]
28. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
29. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507 [TBL] [Abstract][Full Text] [Related]
30. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Verma A; Devine S; Morrow M; Chen YH; Mihalov M; Peace D; Stock W; Pursell K; Wickrema A; Yassine M; Jessop E; van Besien K Bone Marrow Transplant; 2003 May; 31(9):813-6. PubMed ID: 12732890 [TBL] [Abstract][Full Text] [Related]
31. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711 [TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial. Cowley NJ; Owen A; Shiels SC; Millar J; Woolley R; Ives N; Osman H; Moss P; Bion JF JAMA Intern Med; 2017 Jun; 177(6):774-783. PubMed ID: 28437539 [TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors. Yoon HS; Lee JH; Choi ES; Seo JJ; Moon HN; Kim MN; Im HJ Pediatr Transplant; 2009 Nov; 13(7):898-905. PubMed ID: 19032414 [TBL] [Abstract][Full Text] [Related]
34. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493 [TBL] [Abstract][Full Text] [Related]
35. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207 [TBL] [Abstract][Full Text] [Related]
36. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Nakamura R; Cortez K; Solomon S; Battiwalla M; Gill VJ; Hensel N; Childs R; Barrett AJ Bone Marrow Transplant; 2002 Aug; 30(4):235-42. PubMed ID: 12203140 [TBL] [Abstract][Full Text] [Related]
37. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406 [TBL] [Abstract][Full Text] [Related]
38. Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. Alain S; Hantz S; Scieux C; Karras A; Mazeron MC; Szelag JC; Imbert BM; Fillet AM; Gouarin S; Mengelle C; De Wilde A; Cogne N; Champier G; Rogez S; Legendre C; Denis F J Med Virol; 2004 Aug; 73(4):566-73. PubMed ID: 15221901 [TBL] [Abstract][Full Text] [Related]
39. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472 [TBL] [Abstract][Full Text] [Related]
40. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection. Kim DH; Kim JG; Lee NY; Sung WJ; Sohn SK; Suh JS; Lee KS; Lee KB Bone Marrow Transplant; 2004 Jul; 34(1):21-7. PubMed ID: 15133483 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]